Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Jul 13;142(2):141-145.
doi: 10.1182/blood.2022019340.

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Pier Luigi Zinzani  1   2 , Catherine Thieblemont  3 , Vladimir Melnichenko  4 , Krimo Bouabdallah  5 , Jan Walewski  6 , Alejandro Majlis  7 , Laura Fogliatto  8 , A Martin Garcia-Sancho  9 , Beth Christian  10 , Zafer Gulbas  11 , Muhit Özcan  12 , Guilherme Fleury Perini  13 , Herve Ghesquieres  14 , Margaret A Shipp  15 , Seth Thompson  16 , Samhita Chakraborty  16 , Patricia Marinello  16 , Philippe Armand  15
Affiliations
Clinical Trial

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Pier Luigi Zinzani et al. Blood. .

Erratum in

Abstract

Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantation. The end points included objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) according to the investigator per 2007 Response Criteria; overall survival (OS); and safety. In this final analysis, median duration of follow-up was 48.7 months (range, 41.2-56.2). The ORR was 41.5% (complete response, 20.8%; partial response, 20.8%). The median DOR was not reached; no patients who achieved a complete response progressed at the data cutoff. The median PFS was 4.3 months; the 4-year PFS rate was 33.0%. The median OS was 22.3 months; the 4-year OS rate was 45.3%. At the data cutoff, 30 patients (56.6%) had any-grade treatment-related adverse events (AEs); the most common were neutropenia, asthenia, and hypothyroidism. Grade 3/4 treatment-related AEs occurred in 22.6% of the patients; no grade 5 AEs occurred. After 4 years of follow-up, pembrolizumab continued to provide durable responses, with promising trends for long-term survival and acceptable safety in R/R PMBCL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.L.Z. reports advisory/consultancy roles with Secura Bio, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, TG Therapeutics, Takeda, Roche, EUSA Pharma, Kyowa Kirin, Novartis, ADC Therapeutics, Incyte, and BeiGene; and speaker bureau roles with Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therapeutics, Takeda, Roche, EUSA Pharma, Kyowa Kirin, Novartis, Incyte, and BeiGene. C.T. reports advisory/consultancy roles and travel accommodations/expenses with Roche, Incyte, Novartis, Kite/Gilead, Amgen, Takeda, and BMS. K.B. reports honoraria from Takeda, Kite-Gilead, Sandoz, and AbbVie; advisory/consultancy roles with Takeda and Kite-Gilead; and research funding from AbbVie and Takeda. J.W. reports advisory/consultancy roles with Novartis; and research grant/funding from AstraZeneca, BMS Celgene, Epizyme, Gilead, GSK, Incyte, Janssen-Cilag, Karyopharm, Morphosys, MSD, Nanovector, Polish Lymphoma Research Group, Polish Myeloma Consortium, Regeneron, Roche, Seagen, Takeda, and TG Therapeutics. L.F. reports honoraria from AstraZeneca. A.M.G.-S. reports honoraria from Roche, BMS/Celgene, Janssen, Servier, Gilead/Kite, Takeda, EUSA Pharma, and Novartis; advisory/consultancy roles with Roche, BMS/Celgene, Kyowa Kirin, Clinigen, EUSA Pharma, Novartis, Gilead/Kite, Servier, Incyte, Lilly, Takeda, ADC Therapeutics America, and Miltenyi; research grant/funding from Janssen and Teva; and travel/accommodation/expenses from Gilead/Kite, Janssen, Roche, BMS/Celgene, Servier, and Kern Pharma. B.C. reports advisory/consultancy roles with Genentech, MorphoSys, ADC Therapeutics, and GenMab; and research grant/funding from Genentech/Roche, Celgene/BMS, Acerta, Triphase, MorphoSys, SeaGen, and Millennium. Z.G. reports an advisory/consultancy role paid to the institution with BMS and a speaker bureau role paid to the institution with Amgen. M.Ö. reports research grant/funding from AbbVie, Bayer, Janssen, Acerta, Reddy’s, MSD, Roche, and Takeda and travel/accommodation/expenses from AbbVie, Jazz, and Roche. G.F.P. reports advisory/consultancy roles with Janssen, AbbVie, Takeda, and AstraZeneca; speaker bureau roles with Janssen, AbbVie, Takeda, AstraZeneca, and MSD; and travel/accommodation/expenses from Janssen, Takeda, AstraZeneca, and MSD. H.G. reports honoraria from Gilead, Roche, BMS, and AbbVie and advisory/consultancy roles with Gilead and Roche. M.A.S. reports research grant/funding from AstraZeneca, Bayer, BMS, and AbbVie. S.T. reports employment at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, and is a share/stockholder or has stock options in Merck & Co, Inc, Rahway, NJ. S.C. reports employment at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, and is a share/stockholder or has stock options in Merck & Co, Inc, Rahway, NJ. P.M. reports employment at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, and is a share/stockholder or has stock options in Merck & Co, Inc, Rahway, NJ. P.A. reports advisory/consultancy roles with Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, AstraZeneca, Genentech, and Xencor and research grant/funding from Merck, BMS, Affimed, Adaptive, Tensha, Otsuka, Sigma Tau, Genentech/Roche, IGM, and Kite. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Kaplan-Meier estimates of response duration, progression-free survival and overall survival. (A) DOR; (B) PFS; (C) OS. NR, not reached.
See this image and copyright information in PMC

Comment in

References

    1. American Cancer Society Types of B-cell lymphoma. American Cancer Society. 2019. https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma...
    1. Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38(12):1715–1723. - PMC - PubMed
    1. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–3739. - PMC - PubMed
    1. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–862. - PMC - PubMed
    1. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062–2065. - PubMed

Publication types

MeSH terms

Substances